Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 19992004

Gynecological Endocrinology

Volumn 25, Issue 7, 2009, Pages 441-449

  Hurwitz, Barry E ^a,b,c   Henry, Nicole ^a,d   Goldberg, Ronald B ^a,c  

^a UNIVERSITY OF MIAMI   (United States)

^b Department of Biology   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Doctors Hospital   (United States)

Author keywords

Cardiovascular; Metabolic syndrome; Oral contraceptives; Pre menopausal

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT;

ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INSULINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MENTAL DISEASE; METABOLIC SYNDROME X; OBESITY; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; THYROID DISEASE; TREATMENT DURATION;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONTRACEPTIVES, ORAL; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FEMALE; HEALTH SURVEYS; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; PREMENOPAUSE; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 70350686383     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590902770149     Document Type: Article

References (46)

1. ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006;12:483-497.
2. Alonso de Leciñ ana M, Egido JA. Estrogens as neuroprotectants against ischemic stroke. Cerebrovasc Dis 2006;21:48-53.
3. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587.
4. Godsland IF, Winkler U, Lidegaard O, Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 2000;60:721-869.
5. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004;350:1-36.
6. Boyce J, Fawcett JW, Noall EW. Coronary thrombosis and Conovide. Lancet 1963;1:111.
7. Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978;240:2548-2552.
8. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981;305:612-618.
9. Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: A meta-analysis. Contraception 2003;68:11-17.
10. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis. J Clin Endocrinol Metab 2005;90:3863-3870.
11. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304. (Pubitemid 41242486)
12. Grundy SM.Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093-1100.
13. Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006;83:1248-1251.
14. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-1454.
15. Aizawa Y, Kamimura N, Watanabe H, Aizawa Y, Makiyama Y, Usuda Y, Watanabe T, Kurashina Y. Cardiovascular risk factors are really linked in the metabolic syndrome: This phenomenon suggests clustering rather than coincidence. Int J Cardiol 2006;109:213-218.
16. Klaus JR, Hurwitz BE, Llabre MM, Skyler JS, Goldberg RB, Marks JB, Bilsker MS, Schneiderman N. Central Obesity and Insulin Resistance in Cardiometabolic Syndrome: pathways to preclinical cardiovascular structure and function. J Cardio Metab Syndr 2009.
17. Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007;4:S162-S177.
18. National Center for Health Statistics. The National Health and Nutrition Examination Survey (NHANES) 1999-2004 data files. Available at: http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
20. Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998;83: 3025-3230.
21. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287: 356-359.
22. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005;28:2745-4279.
23. Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: The San Antonio Heart Study. Diabetes Care 2006;29:625-630.
24. Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V; WISE Study Group. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: Data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertil Steril 2006;85:1425-1431.
25. Pratt WF, Bachrach CA. What do women use when they stop using pill? Fam Plann Perspect 1987;19:257-266.
26. Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a lowdose oral contraceptive: Two randomized, placebo-controlled trials. Contraception 2001;63:297-302.
27. Hite RC, Bannemerschult R, Fox-Kuchenbecker P, Turck R, Brill K. Large observational trial of a new low dose oral contraceptive containing 20 mg ethinylestradiol and 100 mg Levonorgestrel in Germany. Eur J Contracept Reprod Health Care 1999;4:7-13.
28. Lello S, Vittori G, Paoletti AM, Sorge R, Guardianelli F, Melis GB. Effects on body weight and body composition of a low-dose oral estroprogestin containing ethinyl estradiol 20 microg plus levonorgestrel 100 microg. Gynecol Endocrinol 2007;23:632-637.
29. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-1381.
30. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992;74:64-70.
31. Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab 1994;79:1277-1283.
32. Troisi RJ, Cowie CC, Harris MI. Oral contraceptive use and glucose metabolism in a national sample of women in the United States. Am J Obstet Gynecol 2000;183:389-395.
33. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998;280:533-538.
34. Kim C, Siscovick DS, Sidney S, Lewis CE, Kiefe CI, Koepsell TD. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: The CARDIA Study. Coronary Artery Risk Development in Young Adults. Diabetes Care 2002;25:1027-1032.
35. Cheung MC, Walden CE, Knopp RH. Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. Metabolism 1999;48:658-664.
36. Kemmeren JM, Algra A, Grobbee DE. Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. J Intern Med 2001;250:441-448.
37. Wiegratz I, Lee JH, Kutschera E, Bauer HH, von Hayn C, Moore C, Mellinger U, Winkler UH, Gross W, Kuhl H. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 2002;65:223-229.
38. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 1993;42:1153-1158.
39. Ritsch A, Kaser S, Volgger B, Abfalter E, Sturm W, Gänzer H, Fö ger B, Kirchmair R, Ebenbichler C, Patsch JR. Enhancement of cholesteryl transfer in plasma by hormonereplacement therapy. Metabolism 2002;51:599-604.
40. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.
41. Godsland IF. Biology: Risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas 2004;47:299-303.
42. Schaefer E, Foster D, Zech L, Lindgren F, Brewer Jr H, Levy R. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262-267.
43. Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 1996;16:431-440.
44. Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res 2002;43:383-391.
45. Carr BR. Uniqueness of oral contraceptive progestins. Contraception 1998;58:23S-27S.
46. Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004;69:271-278.